Advertisement

Topics

Low on cash, ImmunoCellular halts study and looks for a lifeline

04:45 EDT 22 Jun 2017 | BioPharmaDive

The microcap biotech is evaluating "strategic alternatives," including a potential merger, restructuring or sale.

Original Article: Low on cash, ImmunoCellular halts study and looks for a lifeline

NEXT ARTICLE

More From BioPortfolio on "Low on cash, ImmunoCellular halts study and looks for a lifeline"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...